-
2022-502079-49-00
5
HIV-1 infection
-
2022-502126-40-00
5
HIV-1 infection
-
2023-505311-20-00
5
Metastatic Non-Small Cell Lung Cancer
-
2024-512754-16-00
5
Prostate cancer
-
2023-505569-95-00
11
Focal Liver Lesion
-
2023-506372-27-00
5
Adult patients, male or female, with chronic pelvic pain syndrome (CPP
-
2023-509392-17-00
5
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515225-28-00
10
Adenocarcinoma of the medium/lower rectum in Stage II (cT3-4 N0) or St
-
2024-516740-26-00
4
Disseminated large B-cell lymphoma
-
2024-516943-14-01
4
Muscle-Invasive Bladder cancer
-
2024-517565-16-00
4
Resectable Locally Advanced Oral Cavity Squamous Cell Carcinoma
-
2024-517759-11-00
6
Inflammatory Bowel Disease
-
2024-517796-21-00
5
Prevention of recurrence after a first episode of Venous Thromboemboli
-
2024-518026-32-00
5
Invasive Breast Cancer
-
2024-518388-37-00
4
Intermediate risk prostate cancer
-
2024-518617-25-00
4
newly diagnosed non-M3 FLT3-positive acute myeloid leukemia
-
2024-518821-13-00
4
Non-cystic Fibrosis Bronchiectasis
-
2024-518835-13-00
5
Suspected Vascular Disease of supra-aortic (carotid/vertebrobasilar),
-
2024-519031-42-00
5
pancreatic ductal adenocarcinoma
-
2024-519087-41-00
5
Breast cancer is the most common form of cancer among women in North A
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2024-520093-34-00
5
Acinar cell prostatic carcinoma
-
2025-521583-35-00
4
non-small cell lung cancer (NSCLC)
-
2025-521651-22-00
4
hormone receptor positive, HER2-negative breast cancer